Public Profile

CureVac

CureVac AG, a pioneering biopharmaceutical company headquartered in Tübingen, Germany, is at the forefront of mRNA technology. Founded in 2000, CureVac has made significant strides in the development of innovative therapies and vaccines, particularly in the fields of oncology and infectious diseases. The company is renowned for its proprietary mRNA platform, which enables the creation of targeted treatments that harness the body’s own immune response. Notable achievements include the advancement of its COVID-19 vaccine candidate, which showcased the potential of mRNA in rapid vaccine development. With a strong market position, CureVac continues to expand its operational reach across Europe and North America, solidifying its role as a leader in the biopharmaceutical industry.

DitchCarbon Score

How does CureVac's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

10

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

26

Industry Benchmark

CureVac's score of 10 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.

44%

Let us know if this data was useful to you

CureVac's reported carbon emissions

CureVac, headquartered in Germany (DE), currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, the company is likely to be engaged in industry-standard practices aimed at reducing carbon footprints, as is common in the biopharmaceutical sector. For a comprehensive understanding of CureVac's climate commitments, further information would be necessary.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. CureVac's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for CureVac is in DE, which has a medium grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

CureVac is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Aldevron, LLC

US
Research and development services (73)
Updated 3 months ago

Pfizer

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

TRILINK BIOTECHNOLOGIES LLC

US
Chemicals nec
Updated 3 days ago

Nutcracker Therapeutics, Inc.

US
Research and development services (73)
Updated 3 days ago

CP Pharmaceuticals Ltd.

GB
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Glaxosmithkline

GB
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers